rethinkTHC Search
Menu
Study breakdown

Italy's accidental CBD liberalization led to significant drops in prescriptions for anxiety, sleep, pain, and psychiatric medications

ObservationalModerate evidence
The takeaway

When light cannabis (CBD products) became unexpectedly available in Italy in 2017, prescription sales of anxiolytics, sedatives, opioids, antidepressants, and antipsychotics significantly declined.

Health economists, drug policy analysts, medical cannabis advocates and skeptics

CBD availability reduced prescriptions across five drug categories including opioids

What the researchers found

Using the staggered rollout of light cannabis shops across Italian provinces, the study documented significant substitution effects between CBD products and five prescription drug categories: anxiolytics, sedatives, opioids, antidepressants, and antipsychotics.

Why it matters

This provides some of the strongest economic evidence that legal access to CBD products leads people to substitute away from prescription medications, with implications for drug policy and healthcare costs.

The numbers in context

Significant substitution effects documented for five drug categories: anxiolytics, sedatives, opioids, antidepressants, and antipsychotics. The study used high-frequency data across all Italian provinces.

How the study worked

Natural experiment exploiting Italy's unintended 2017 liberalization of CBD-based "light cannabis." High-frequency prescription drug sales data analyzed using the staggered local availability of light cannabis across Italian provinces as a quasi-experimental design.

What this study cannot tell us

Cannot identify individual-level substitution; ecological design using province-level data; cannot determine whether patients benefited from switching to CBD; unregulated CBD products may have variable quality.

How to read the evidence

Clever natural experiment design using staggered rollout, but ecological data cannot confirm individual-level substitution or health outcomes.

When this study was published

Published in 2020.

The bigger picture

The pattern of prescription substitution suggests people may be self-treating symptoms of anxiety, pain, sleep disorders, and mood conditions with CBD products, whether or not clinical evidence supports those uses.

Questions still open

  • Are patients who switched to CBD experiencing better or worse outcomes? Could regulated CBD access reduce healthcare costs if substitution effects are confirmed?

Common questions

What is "light cannabis" in Italy?
In 2017, a regulatory gray area allowed the sale of CBD-based cannabis products with negligible THC levels in Italy. This created an unintended natural experiment that researchers used to study the effect of CBD availability on prescription drug use.
Does this mean CBD is as effective as prescription medications?
The study shows people substituted CBD for prescriptions, but it cannot determine whether they experienced equivalent symptom relief. Some patients may have benefited, while others may have received less effective treatment.

Read the original research

Do-It-Yourself medicine? The impact of light cannabis liberalization on prescription drugs.

Journal of health economics, 74, 102371

Citation

Carrieri, Vincenzo; Madio, Leonardo; Principe, Francesco. (2020). Do-It-Yourself medicine? The impact of light cannabis liberalization on prescription drugs.. Journal of health economics, 74, 102371. https://doi.org/10.1016/j.jhealeco.2020.102371

Explore the wider topic